Skip to main content

Reversible posterior leukoencephalopathy syndrome: diagnosis and management in the setting of lung transplantation

Buy Article:

$43.00 plus tax (Refund Policy)

Reversible posterior leukoencephalopathy syndrome (RPLS) is a potentially devastating early complication of calcineurin inhibitor (CNI) therapy in solid organ transplantation. Management centres on cessation of CNI therapy; however, this strategy is complicated in lung transplantation because of the threat of allograft rejection, or, if CNI is replaced with mammalian target of rapamycin‐based immunosuppression, poor wound healing and bronchial dehiscence. We describe four cases of RPLS after lung transplantation, emphasizing the diagnostic and management approach required to maintain a healthy allograft and ensure that RPLS is, as the name suggests, reversible.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: cyclosporine; immunosuppressive agents; lung transplantation; posterior leukoencephalopathy syndrome; tacrolimus

Document Type: Research Article

Affiliations: Queensland Centre for Pulmonary Transplantation and Vascular Disease, the Prince Charles Hospital, Brisbane, Queensland, Australia

Publication date: 2010-10-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more